$2.00
2.84% today
Nasdaq, Feb 28, 05:17 pm CET
ISIN
US45773H2013
Symbol
INO

Inovio Pharmaceuticals, Inc. Stock price

$1.94
-0.33 14.54% 1M
-5.49 73.89% 6M
+0.11 6.01% YTD
-7.08 78.49% 1Y
-36.94 95.01% 3Y
-50.38 96.29% 5Y
-82.96 97.72% 10Y
Nasdaq, Closing price Thu, Feb 27 2025
-0.04 2.02%
ISIN
US45773H2013
Symbol
INO
Sector

Key metrics

Market capitalization $70.03m
Enterprise Value $-2.32m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF 0.02
EV/Sales (TTM) EV/Sales -11.60
P/S ratio (TTM) P/S ratio 350.15
P/B ratio (TTM) P/B ratio 0.69
Revenue growth (TTM) Revenue growth -76.18%
Revenue (TTM) Revenue $200.00k
EBIT (operating result TTM) EBIT $-119.42m
Free Cash Flow (TTM) Free Cash Flow $-111.18m
Cash position $84.80m
EPS (TTM) EPS $-4.48
P/E forward negative
P/S forward 524.70
EV/Sales forward negative
Short interest 14.99%
Show more

Is Inovio Pharmaceuticals, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,809 stocks worldwide.

Inovio Pharmaceuticals, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

6 Analysts have issued a Inovio Pharmaceuticals, Inc. forecast:

3x Buy
50%
3x Hold
50%

Analyst Opinions

6 Analysts have issued a Inovio Pharmaceuticals, Inc. forecast:

Buy
50%
Hold
50%

Financial data from Inovio Pharmaceuticals, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
0.20 0.20
76% 76%
100%
- Direct Costs 2.53 2.53
46% 46%
1,265%
-2.33 -2.33
39% 39%
-1,165%
- Selling and Administrative Expenses 35 35
18% 18%
17,290%
- Research and Development Expense 80 80
28% 28%
39,995%
-117 -117
26% 26%
-58,445%
- Depreciation and Amortization 2.53 2.53
46% 46%
1,265%
EBIT (Operating Income) EBIT -119 -119
26% 26%
-59,712%
Net Profit -113 -113
31% 31%
-56,440%

In millions USD.

Don't miss a Thing! We will send you all news about Inovio Pharmaceuticals, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Inovio Pharmaceuticals, Inc. Stock News

Neutral
Seeking Alpha
16 days ago
Inovio Pharmaceuticals Inc (NASDAQ:INO ) Oppenheimer 35th Annual Healthcare Life Sciences Conference February 12, 2025 3:20 PM ET Company Participants Jacqui Shea - CEO and President Conference Call Participants Jay Olson - Oppenheimer Jay Olson And our discussion with Inovio. It's a pleasure to introduce Jacqui Shea, CEO and President.
Neutral
PRNewsWire
16 days ago
Data shows that INO-3107 induced new populations of T cells in the blood that traveled to airway tissue and were associated with clinical benefit as measured by reduced need for surgeries PLYMOUTH MEETING, Pa. , Feb. 12, 2025 /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related dis...
Neutral
PRNewsWire
18 days ago
Poster will describe loss of detectable HPV-6 in Recurrent Respiratory Papillomatosis patients following treatment with INO-3107 PLYMOUTH MEETING, Pa. , Feb. 10, 2025 /PRNewswire/ --  INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced tha...
More Inovio Pharmaceuticals, Inc. News

Company Profile

Inovio Pharmaceuticals, Inc. is a late-stage biotechnology company. It engages in the discovery, development, and commercialization of DNA-based immunotherapies and vaccines. The firm's drug candidates include SynCon immunotherapies which helps break the immune system's tolerance of cancerous cells; and CELLECTRA delivery system which facilitates optimized cellular uptake of the SynCon immunotherapies. The company was founded by David B. Weiner on June 29, 1983 and is headquartered in Plymouth Meeting, PA.

Head office United States
CEO Jacqueline Shea
Employees 122
Founded 1983
Website www.inovio.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today